Comparative Pharmacology
Head-to-head clinical analysis: PREGABALIN versus QUDEXY XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREGABALIN versus QUDEXY XR.
PREGABALIN vs QUDEXY XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the alpha2-delta subunit of voltage-gated calcium channels, reducing calcium influx and decreasing release of excitatory neurotransmitters (e.g., glutamate, norepinephrine, substance P).
Stabilizes neuronal membranes and inhibits repetitive firing of action potentials via blockade of voltage-gated sodium channels; also enhances GABAergic activity and inhibits glutamate release.
Initial: 75 mg orally twice daily; may increase to 150 mg twice daily within 1 week; maximum: 600 mg/day in divided doses.
Initial dose 25 mg orally twice daily; titrate by 25-50 mg/day every 1-2 weeks to target dose of 200-400 mg/day in two divided doses. Maximum 400 mg/day.
None Documented
None Documented
Clinical Note
moderatePregabalin + Fluticasone propionate
"The therapeutic efficacy of Fluticasone propionate can be increased when used in combination with Pregabalin."
Clinical Note
moderatePregabalin + Haloperidol
"The therapeutic efficacy of Haloperidol can be increased when used in combination with Pregabalin."
Clinical Note
moderatePregabalin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Pregabalin."
Clinical Note
moderatePregabalin + Fluconazole
Terminal elimination half-life is approximately 6.3 hours. In patients with renal impairment, half-life is prolonged (up to 48 hours in anuria). Requires dose adjustment based on creatinine clearance.
Terminal elimination half-life is approximately 70-90 hours after multiple dosing, supporting twice-daily dosing; requires slow titration to steady state (2-3 weeks).
Primarily renal excretion as unchanged drug (92-99% of dose). Approximately 0.1% is metabolized. No biliary or fecal elimination of significance.
Renal: approximately 70% as unchanged drug; fecal: approximately 20%; biliary: minor (<5%).
Category A/B
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Fluconazole can be increased when it is combined with Pregabalin."